News

Bullous pemphigoid is known to be associated with increased eotaxin-1 levels in serum and blister fluids. Immune recently started a Phase IIa open label clinical trial in bullous

GSK will increase potential milestone payments to Avalon Ventures from $40m to $50m for each biotech formed. The companies have also formed the seventh out of ten biotechs

The company completed negotiations to operate a significant proportion of the 70-acre Charnwood Campus in Loughborough, England, UK. Almac will occupy the formulation development and analytical testing plants

Rizaport, 5 mg and 10 mg, is an oral thin film formulation of rizatriptan benzoate. It is being developed by RedHill Biopharma and IntelGenx. It is the first

If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously. Amgen executive vice president of research and development Sean Harper said: "We’re pleased that

Xtampza ER is an extended-release, oral formulation of oxycodone, in development to manage pain severe enough for daily, long-term opioid treatment and for which alternative treatment options are

Sulfatinib inhibits the tyrosine kinase activity related with the vascular endothelial growth factor receptor (VEGFR) and fibroblast growth receptor (FGFR), which plays a role in tumour growth. The

US-based ZS Pharma develops and commercializes highly selective, non-absorbed drugs for the treatment of renal, cardiovascular, liver and metabolic disorders. The company employs about 200 people across three

The investigational drug SM04690 is a small molecule inhibitor of the Wnt pathway. The approximately 400 patient trial will study three different doses of SM04690 against a placebo,